Adalta logo

1AD - Adalta Share Price

A$0.1 0.0  5.3%

Last Trade - 3:46am

Sector
Healthcare
Size
Micro Cap
Market Cap £7.56m
Enterprise Value £4.62m
Revenue £1.90m
Position in Universe 1306th / 1832
Bullish
Bearish
Unlock 1AD Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

1AD Revenue Unlock 1AD Revenue

Net Income

1AD Net Income Unlock 1AD Revenue

Normalised EPS

1AD Normalised EPS Unlock 1AD Revenue

PE Ratio Range

1AD PE Ratio Range Unlock 1AD Revenue

Dividend Yield Range

1AD Dividend Yield Range Unlock 1AD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1AD EPS Forecasts Unlock 1AD Revenue
Profile Summary

AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated June 22, 2006
Public Since August 22, 2016
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 150,569,426
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address Shop 14 330 Collins St, MELBOURNE, 3000, Australia
Web http://www.adalta.com.au/
Phone +61 3 94795159
Auditors Butler Settineri (Audit) Pty Ltd
1AD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 1AD
Upcoming Events for 1AD
Similar to 1AD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.